Testicular cancer marker M371
Clinical information
The M371 testicular cancer test can detect testicular germ cell tumours with high diagnostic certainty. Studies show sensitivities of 89-96% and specificities of over 90%. MicroRNA miR-371a-3p expressed by testicular germ cell tumour tissue correlates closely with the presence, stage and size of the testicular tumour.
Seminomas and non-seminomas (with the exception of teratomas) can be reliably detected with the M371 testicular cancer test. Due to its very high sensitivity and specificity, miR-371a-3p levels should be determined pre- and postoperatively in addition to the established parameters AFP, β-hCG and LDH. After orchiectomy, this method is a quicker way of confirming that all the tumour tissue has been removed, as miR-371a-3p has a significantly shorter half-life than the traditional serum markers.
The analysis can be used in the following clinical situations:
- To support primary diagnostics
- To determine the success of surgery
- To monitor the success of treatment
- To monitor for relapses
Price: CHF 809.45
As a rule, the health insurance company will cover the costs of the test. However, it is possible that the health insurance company will refuse to cover the costs as part of the basic insurance and/or any supplementary insurance. In this case, the patient must bear the costs themselves.
Associated profile 02308.
